Introduction
In commenting on our systematic review and meta-analysis of the prevalence of use of non-medical anabolic androgenic steroid(s) (AAS) in the Nordic countries (Sagoe, Torsheim, Molde, Andreassen, & Pallesen, 2015a) , Bilgrei and Sandøy (2015) argue that AAS use in these countries should not be considered a major public health problem. Instead, they argue that AAS use in the Nordic countries should be regarded as a problem among smaller subgroups of users.
Although Bilgrei and Sandøy provide a useful contribution to the discussion on the use of AAS in the Nordic countries, it is our view that their comments have little impact on our conclusion: "…though subject to some limitations…non-medical AAS use should be regarded as a serious public health problem in the Nordic countries" (p. 7).
In this piece, we respond to the comments of Bilgrei and Sandøy based on the premises they provide for their conclusion: prevalence, evolvement and severity.
Prevalence of AAS use
Bilgrei and Sandøy note, and rightly so, that the preponderance of lifetime prevalence rates reported in our included studies ranges from 1 to 2%, with a few exceptions in studies of subpopulations such as bodybuilders, prisoners and drug users. Thus, in no part of our work do we conclude that AAS use is a "growing public health problem" as alleged by Bilgrei and Sandøy (p. 26) . We therefore find Bilgrei and Sandøy's "evolution" argument on our conclusion untenable.
"Severity" of AAS use
There is extant literature on the negative (Cunningham, Lumia, & McGinnis, 2013; Kicman & Gower, 2003; Landry & Primos, 1990; Pagonis et al., 2006) . Therefore, in respect of our study, we find the "severity" argument of Bilgrei and Sandøy peripheral.
Conclusion
Based on our line of argument provided above, we find the points raised by Bilgrei and Sandøy of little impact on our conclusion. We discuss in our work the chal- 
